About

Dr. Véronique Lecault is a co-founder of AbCellera and has served in various positions since November 2012, as a member of the Board of Directors since August 2018, as Chief Operating Officer from January 2019 to February 2025, and as Chief Technology Officer since February 2025. She co-invented the high-throughput microfluidic platform that is now a core part of AbCellera's antibody-discovery technology and oversees the company's process development, clinical manufacturing, quality, engineering, data science and infrastructure functions. She holds a B.A.Sc. in Chemical Engineering / Honours B.Sc. in Biochemistry (Biotechnology) from the University of Ottawa and a Ph.D. in Chemical and Biological Engineering from the University of British Columbia.

Roles

AbCellera Biologics Inc.
Chief Technology Officer and Director · Current role
November 2012–present
AbCellera Biologics Inc.
Chief Operating Officer · Transitioned to Chief Technology Officer effective February 18, 2025
January 2019 - February 2025
University of British Columbia
Ph.D. researcher · Co-invented the high-throughput microfluidic platform underlying AbCellera's core technology

Fixed Compensation

FY 2025
Salary
$454,000
ComponentAnnual base salary earned in FY2025 (USD)
All other compensation
$23,244
ComponentRRSP employer contributions
Total compensation
$2,315,758

Performance Compensation

Data from FY 2025

Cash incentive

Bonus
$204,402
Target Opportunity
PlanDiscretionary annual cash incentive bonus for 2025 (45% of base-salary target)

Stock awards

Stock options
$1,634,113
FormStock options, ASC 718 grant-date fair value (NEO long-term incentives are 100% options)

Also at AbCellera Biologics Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

You're subscribed.

Thanks for signing up.